wondering whether a different combo trial could be run in R/R AML so pricing isn’t eroded.
I don’t know much about how the price is determined, so based on the triangle report favouring a cardio protect + anti cancer effect.
thinking outside the box, to achieve this could Race do a 3 in 1 combo trial. Here is my thoughts:
R/R AML 3-in-1 #Decatabine + Venetoclax + Bisantrene
Bisantrene synergises with Decitabine
Bisantrene synergises with Venetoclax
Decitabine promotes FTO expression
Venetoclax is cardiotoxic
R/R AML overexpresses FTO
This supports Cardio protect, anti cancer and FTO all in one. Anything I’m missing why this would not work be a good idea scientifically or commercially?
How long would it take to check the combo invitro for synergy and cardio protect?
- Forums
- ASX - By Stock
- Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
wondering whether a different combo trial could be run in R/R...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1100 | $1.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 4999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31221 | 1.625 |
1 | 5000 | 1.620 |
1 | 30000 | 1.615 |
2 | 16249 | 1.610 |
4 | 26875 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 4999 | 1 |
1.720 | 17729 | 2 |
1.730 | 25792 | 1 |
1.750 | 508 | 1 |
1.780 | 4483 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |